Catalyst Pharmaceuticals Inc (CPRX)
15.47
+0.43
(+2.86%)
USD |
NASDAQ |
Jun 28, 16:00
15.47
0.00 (0.00%)
After-Hours: 20:00
Catalyst Pharmaceuticals Research and Development Expense (Annual): 93.15M for Dec. 31, 2023
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 93.15M |
| December 31, 2022 | 19.79M |
| December 31, 2021 | 16.94M |
| December 31, 2020 | 16.50M |
| December 31, 2019 | 18.84M |
| December 31, 2018 | 19.92M |
| December 31, 2017 | 11.38M |
| December 31, 2016 | 11.37M |
| December 31, 2015 | 11.80M |
| December 31, 2014 | 10.12M |
| December 31, 2013 | 8.097M |
| Date | Value |
|---|---|
| December 31, 2012 | 2.660M |
| December 31, 2011 | 3.384M |
| December 31, 2010 | 2.307M |
| December 31, 2009 | 5.097M |
| December 31, 2008 | 8.710M |
| December 31, 2007 | 2.991M |
| December 31, 2006 | 0.9891M |
| December 31, 2005 | 1.330M |
| December 31, 2004 | 0.3783M |
| December 31, 2003 | |
| December 31, 2002 | 0.1377M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
16.50M
Minimum
2020
93.15M
Maximum
2023
33.04M
Average
18.84M
Median
2019
Research and Development Expense (Annual) Benchmarks
| Pfizer Inc | 10.68B |
| Sarepta Therapeutics Inc | 877.39M |
| PTC Therapeutics Inc | 666.56M |
| Corcept Therapeutics Inc | 184.35M |
| Vertex Pharmaceuticals Inc | 3.163B |